Results 261 to 270 of about 86,629 (276)

Bortezomib-Encapsulated CuS/Carbon Dot Nanocomposites for Enhanced Photothermal Therapy via Stabilization of Polyubiquitinated Substrates in the Proteasomal Degradation Pathway

ACS Nano, 2020
Cailing Chen, Yangyang Du, Yu Han
exaly  

Bortezomib

Reactions Weekly, 2014
openaire   +1 more source

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Lancet Oncology, The, 2019
Paul G Richardson, Albert Oriol
exaly  

Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis

Journal of Clinical Oncology, 2020
Efstathios Kastritis, Bertrand Arnulf, Arnaud Jaccard   +2 more
exaly  

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Lancet Haematology,the, 2020
Michele Cavo, Francesca Gay
exaly  

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

Lancet Oncology, The, 2017
Hartmut Goldschmidt, Ruben Niesvizky, Douglas Joshua   +2 more
exaly  

Bortezomib

Reactions Weekly, 2017
openaire   +2 more sources

Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Journal of Clinical Oncology, 2006
Richard I Fisher, Benjamin Djulbegovic, Sagar Lonial   +2 more
exaly  

Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

Journal of Clinical Oncology, 2007
Robert Z Orlowski, Pieter Sonneveld, Roman Hajek   +2 more
exaly  

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Leukemia, 2011
Ashraf Badros, Andrew R Belch, P Leif Bergsagel   +2 more
exaly